These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
427 related items for PubMed ID: 16613681
21. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Kim JE, Yoo C, Lee DH, Kim SW, Lee JS, Suh C. Ann Hematol; 2010 Apr; 89(4):391-7. PubMed ID: 19844712 [Abstract] [Full Text] [Related]
22. Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma. Katodritou E, Verrou E, Hadjiaggelidou C, Gastari V, Laschos K, Kontovinis L, Kapetanos D, Constantinou N, Terpos E, Zervas K. Am J Hematol; 2008 Sep; 83(9):697-701. PubMed ID: 18626886 [Abstract] [Full Text] [Related]
23. [Long-term survival and prognostic factors in multiple myeloma treated with conventional chemotherapy. Report of 109 cases]. Ben Abid H, Meddeb B, Ben Abdallah M, Bel Hadj Ali Z, Hafsia R, Ben Lakhal R, Gouider E, Aissaoui L, Landoulsi I, ben Abdeladhim A, Hafsia A. Tunis Med; 2000 Dec; 78(12):705-12. PubMed ID: 11155374 [Abstract] [Full Text] [Related]
24. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels. Scudla V, Budíková M, Fischerová E, Zadrazil J, Indrák K. Acta Univ Palacki Olomuc Fac Med; 1991 Dec; 130():201-12. PubMed ID: 1838869 [Abstract] [Full Text] [Related]
25. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy]. Pertuiset E, Chevret S, Lioté F, Delauche MC, Bardin T, Dryll A, Kuntz D. Ann Med Interne (Paris); 1992 Dec; 143(8):519-24. PubMed ID: 1303595 [Abstract] [Full Text] [Related]
26. [Classification, staging and prognostic indices for multiple myeloma]. Hotta T. Nihon Rinsho; 2007 Dec; 65(12):2161-6. PubMed ID: 18069256 [Abstract] [Full Text] [Related]
27. [Prognostic importance of beta-2-microglobulin in multiple myeloma]. Avilés A, Zepeda G, Guzmán R, Talavera A, García EL, Díaz-Maqueo JC. Rev Invest Clin; 1992 Dec; 44(2):215-20. PubMed ID: 1439309 [Abstract] [Full Text] [Related]
28. IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients. Shimamoto Y. Cancer Detect Prev; 1995 Dec; 19(5):426-35. PubMed ID: 7585729 [Abstract] [Full Text] [Related]
29. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. Komai Y, Saito K, Sakai K, Morimoto S. BJU Int; 2007 Jan; 99(1):77-80. PubMed ID: 16956357 [Abstract] [Full Text] [Related]
30. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment. Urbańska-Ryś H, Robak T. Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474 [Abstract] [Full Text] [Related]
31. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, Adachi H, Kurogi J, Tajiri N, Inoue K, Niizeki T, Koga H, Imaizumi T, Kojiro M, Sata M. Liver Int; 2007 Oct; 27(8):1091-7. PubMed ID: 17845537 [Abstract] [Full Text] [Related]
32. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma. Takada S, Morita K, Hayashi K, Matsushima T, Sawamura M, Murakami H, Nojima Y. Eur J Haematol; 2005 Dec; 75(6):505-10. PubMed ID: 16313263 [Abstract] [Full Text] [Related]
33. Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma. Hsiao LT, Yang CF, Yang SH, Gau JP, Yu YB, Hong YC, Liu CY, Liu JH, Chen PM, Chiou TJ, Tzeng CH. Eur J Haematol; 2012 Feb; 88(2):159-66. PubMed ID: 21973045 [Abstract] [Full Text] [Related]
34. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD, Goldschmidt H. Clin Cancer Res; 2002 Nov; 8(11):3377-82. PubMed ID: 12429624 [Abstract] [Full Text] [Related]
35. [Prognositic factors in multiple myeloma]. Nagura E. Nihon Rinsho; 2007 Dec; 65(12):2351-6. PubMed ID: 18069282 [Abstract] [Full Text] [Related]
36. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification]. Pfannschmidt J, Muley T, Hoffmann H, Bülzebruck H, Dienemann H. Dtsch Med Wochenschr; 2006 Nov 24; 131(47):2643-8. PubMed ID: 17109272 [Abstract] [Full Text] [Related]
37. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters. Bhatti SS, Kumar L, Dinda AK, Dawar R. Am J Hematol; 2006 Sep 24; 81(9):649-56. PubMed ID: 16845660 [Abstract] [Full Text] [Related]
38. Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma. Umeda M, Okuda S, Izumi H, Nagase D, Fujimoto Y, Sugasawa Y, Arai C, Natori K, Katoh M, Kuraishi Y. Ann Hematol; 2006 Jul 24; 85(7):469-73. PubMed ID: 16528526 [Abstract] [Full Text] [Related]
39. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis]. Scudla V, Budíková M, Fischerová E, Raska I, Vavrdová V. Vnitr Lek; 1991 Apr 24; 37(4):342-51. PubMed ID: 2053304 [Abstract] [Full Text] [Related]
40. [Expression and clinical significance of beta-catenin in multiple myeloma]. Li J, Zhang DB, Luo SK, Zhao Y, Huang BH, Gu JL. Ai Zheng; 2007 Sep 24; 26(9):1010-4. PubMed ID: 17927863 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]